POLYMORPHISM Flashcards

1
Q

What approach is used to set acceptance criteria for polymorphism?

A
  • Decision tree approach
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What do trees 1 and 2 consider?

A
  • Whether polymorphism is exhibited by the drug substance

- Whether the different polymorphic forms can affect performance of the drug product

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What does tree 3 consider and when is it applied?

A
  • Applied when polymorphism demonstrated for drug substance and shown to affect properties
  • Considers potential for change in polymorphic forms in drug product
  • Considers whether such a change has effect on product performance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Explain steps in tree 1.

A
  • Conduct polymorphism screen on drug substance
  • Can diff polymorphs be formed?
    1) NO - no further action
    2) YES - Characterise the forms
    e.g Xray powder diffraction, microscopy, spectroscopy
    GO TO TREE 2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Explain steps in tree 2

A
  • Use this tree if diff polymorphic forms present
  • Do the forms have differing properties e.g solubility, stability, melting point…
    1) NO - no further action
    2) YES…
  • Is drug product safety, performance or efficacy affected?
    1) NO - no further action
    2) YES…
  • Set acceptance criterion for polymorph content in drug substance
  • GO TO TREE 3
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Explain steps in tree 3

A
  • Does drug product performance testing provide adequate control if polymorph ratio changes e.g dissolution
    1) YES - establish acceptance criteria for relevant performance tests2
    2) NO - Monitor polymorph form during stability of drug product…
  • Does a change occur which could affect safety or efficacy?
    1) NO - No need to set acceptance criteria for polymorph change in drug product
    2) YES - Establish acceptance criteria which are consistent with safety and/or efficacy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why is production of Sulphathiazole an issue in terms of polymorphism?

A
  • 4 diff polymorphic forms and more being discovered
  • Form 1 has highest aq solubility
  • Form 1 has lowest yield stress and therefore easiest to compress into tablets
  • All polymorphs can be grown
  • Different properties
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Name 2 pieces of analytical equipment used regularly for evaluation of solid state crystal properties…

A

1) Powder x-ray diffraction
- Determine crystal structure and quantitative detection of polymorphs and crystallinity

2) Differential scanning calorimetry (DSC)
- Melting behaviour, quantitative detection of crystal forms (hydrates, solvates, polymorphs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

The higher the temperature the crystal polymorph melts at the ___ the stability

A

HIGHER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Why would you change a drug from its free base or acid to a particular salt form?

A
  • Modifies chemical and biological properties of the drug without modifying its structure
  • Improves sol, diss rate, abs and/or physiochem properties e.g stability, hygroscopicity
  • Various salts of same active drug are distinct products with own properties which relate to diffs in clinical efficacy and safety e.g diff BA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

A decision tree approach to salt selection can be used. Outline the decisions in the tree.

A
  • CRYSTALLINITY
  • can crystalline salts be prepared

HYGROSCOPICITY
- does the salt deliquesce at high humidity

SOLUBILITY
- Doe the salt have aqueous solubility

STABILITY
- Is the salt physically stable under accelerated conditions

POLYMORPHISM
- Are there multiple polymorphs of the salt
(IF NO THEN CANDIDATE)

CONTROL
- Can the process be controlled to produce desired form
(IF YES THEN CANDIDATE)
(IF NO THEN SECONDARY CANDIDATE)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

_____ is the most commonly used salt for basic drugs as it has a ____ pKa

A

Hydrochloride

- LOW pKa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Why would you reformulate a salt form due to reduced stability?
-Give an example…

A

STABILITY

  • Propoxyphene HCl salt
  • Used with Aspirin
  • Unstable when in close contact with each other!
  • Reformulate propoxyphene HCl salt to napsylate salt
  • Overcome instability issue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Why would you reformulate a salt form due to reduced toxicity?
-Give an example…

A

TOXICITY

  • Some cations and anions are associated with toxic effects
  • e.g Lithium kidney
  • Change salt form to reduce toxic potential
  • e.g to one which is slowly abs in GI tract as less toxic than those that are rapidly abs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Why would you reformulate a salt form due to stability (hygroscopicity) issues?
-Give an example…

A

STABILITY (HYDROSCOPICITY)

  • Stability reduced if hygroscopic
  • salts of mineral acids are polar
  • ionised polar groups are hydrophilic and lead to hygroscopicity
  • if drug susceptibly to hydrolytic degradation then can reduce stability
  • Stability enhanced if introduce hydrophobic salt forming acid

e. g Xilobam tablets have high water sol sulphate salt of drug
- salt readily hydrolysed and dissolves in surface moisture
- introduce hydrophobic aryl sulphonic acid and barrier to dissolution so more stable in humid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why would you reformulate a drug with reduced thermal stability?
Give an example

A
  • Hydrochloride form of lincomycin undergoes thermal degradation
  • change to cyclamate form and more stable!
  • Procaine salt of Penicillin G is unstable
  • Sodium of potassium salts of Penicillin G can withstand high temps
17
Q

Give an example of how a racemic mixture can cause issues.

A
  • Thalidomide
  • Was given as D and L racemic mixture
  • L teratogenic but D active sedative
  • pH in body causes racemizing (both enantiomers formed in body)
18
Q

How can issues with racemic mixtures be overcome?

A
  • Racemic switch
  • Develop single-enantiomer form of drug that was first approved as a racemate
  • e.g single enantiomer of racemic salbutamol
  • L salbutamol avoids possible side effects that rise in D form